中文摘要：

目的通过超声评估痰瘀同治方药对颈动脉粥样硬化斑块负荷及灰阶中位值的影响。方法符合入选标准的100例颈动脉粥样硬化病人随机分为他汀对照组（50例）和复方中药组（50例）。他汀对照组予以常规剂量的阿托伐他汀,10 mg口服,每日1次;中药干预予以常规剂量的阿托伐他汀联合复方中药胶囊,中药胶囊2粒口服,每日3次。两组均治疗随访9个月,在治疗基线及随访9个月后行彩色多普勒超声检查颈动脉内径、斑块稳定性以及斑块灰阶中位值。收集两组随访中发生的心血管事件及不良反应的数据。结果复方中药组在治疗后颈动脉内径、斑块稳定性优于对照组,特别是斑块的灰阶中位值在中药干预组表现为显著升高（P〈0.05）,而他汀对照组无显著改变;两组在心脑血管事件和不良反应方面无统计学意义（P〉0.05）。结论在他汀的基础上联用痰瘀同治方药,可进一步抑制颈动脉粥样硬化斑块的进展,安全性较好,并能显著改善斑块的稳定性。

英文摘要：

Objoctive To evaluate the effects of eliminating sputum and removing stasis formulation （ESRSF） on carotid atherosclerotic plaque burden and greyscale median among patients using ultrasound.Methods One hundred patients with carotid atherosclerotic plaques were randomly divided into two groups：control group（ n = 50） treated with atorvastatin,and treatment group（ n = 50）treated with atorvastatin plus ESRSF.AII patients were followed up for 9 months, and investigated the atherosclerosis burden within carotid arteries by ultrasound at the baseline and ending points, respectively.Parameters including carotid artery diameters, plaque stability and greyscale median （GSM）were collected and analyzed by an independent sonographer blind to the patient grouping.And major cardiovascular events and adverse events were collected during the follow - up.Results The carotid artery diameters and plaque stability in treatment group were better than that in control group （ P 〈0.05）.GSM was increased in treatment group （ P 〈0.05）.Conclusion Atorvastatin plus ESRSF can provide further protection against the carotid artery atherosclerotic lesions and promote the stability of the plaques, without any additional risk.